Surveillance, epidemiology and prevention of Hepatitis B
Results of the EUROHEP.NET feasibility survey
D. Radun1, G. Rasch1, Eurohep.net team²

1 Robert Koch Institut, Berlin
2 University of Antwerp, Belgium

Different surveillance systems, epidemiology, burden of disease and prevention programmes for these infectious diseases.

The Quality of Life Programme of the fifth framework of the European Community for research. This project addresses issues related to surveillance and prevention of hepatitis A and B. The primary objective is to facilitate the development of European-wide surveillance systems, to address issues related to surveillance and prevention and to facilitate the progress of these countries towards enhanced control of hepatitis A and B.

### Surveillance System

**Clinicians**

**Individual data**

**Local authority: Gesundheitsamt**

Merge data from clinical and laboratory

**Unspecified**

**Incidence of reported reports**

**Age specific incidence**

**Gesundheitsbehörden der Bundesländer (State Health Authority)**

**National Surveillance System:**

See footnote nr. 2

### Epidemiology

**Cases defined for laboratory surveillance in Germany, 1992-2001**

<table>
<thead>
<tr>
<th>Year</th>
<th>0-9</th>
<th>10-19</th>
<th>20-29</th>
<th>30-39</th>
<th>40</th>
<th>45-64</th>
<th>65+</th>
</tr>
</thead>
<tbody>
<tr>
<td>1992</td>
<td>0.9</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>2%</td>
<td>0.2%</td>
<td>0.0%</td>
</tr>
<tr>
<td>1993</td>
<td>2.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>2%</td>
<td>0.2%</td>
<td>0.0%</td>
</tr>
<tr>
<td>1994</td>
<td>3.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>2%</td>
<td>0.2%</td>
<td>0.0%</td>
</tr>
<tr>
<td>1995</td>
<td>4.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>2%</td>
<td>0.2%</td>
<td>0.0%</td>
</tr>
<tr>
<td>1996</td>
<td>5.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>2%</td>
<td>0.2%</td>
<td>0.0%</td>
</tr>
<tr>
<td>1997</td>
<td>6.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>2%</td>
<td>0.2%</td>
<td>0.0%</td>
</tr>
<tr>
<td>1998</td>
<td>7.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>2%</td>
<td>0.2%</td>
<td>0.0%</td>
</tr>
<tr>
<td>1999</td>
<td>8.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>2%</td>
<td>0.2%</td>
<td>0.0%</td>
</tr>
<tr>
<td>2000</td>
<td>9.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>2%</td>
<td>0.2%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

**Incidence per 100 000**

<table>
<thead>
<tr>
<th>Year</th>
<th>0-9</th>
<th>10-19</th>
<th>20-29</th>
<th>30-39</th>
<th>40</th>
<th>45-64</th>
<th>65+</th>
</tr>
</thead>
<tbody>
<tr>
<td>1992</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>2.9</td>
<td>1.1</td>
<td>0.0</td>
</tr>
<tr>
<td>1993</td>
<td>0.1</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>2.3</td>
<td>1.2</td>
<td>0.0</td>
</tr>
<tr>
<td>1994</td>
<td>0.2</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>2.3</td>
<td>1.2</td>
<td>0.0</td>
</tr>
<tr>
<td>1995</td>
<td>0.3</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>2.3</td>
<td>1.2</td>
<td>0.0</td>
</tr>
<tr>
<td>1996</td>
<td>0.4</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>2.3</td>
<td>1.2</td>
<td>0.0</td>
</tr>
<tr>
<td>1997</td>
<td>0.5</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>2.3</td>
<td>1.2</td>
<td>0.0</td>
</tr>
<tr>
<td>1998</td>
<td>0.6</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>2.3</td>
<td>1.2</td>
<td>0.0</td>
</tr>
<tr>
<td>1999</td>
<td>0.7</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>2.3</td>
<td>1.2</td>
<td>0.0</td>
</tr>
<tr>
<td>2000</td>
<td>0.8</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>2.3</td>
<td>1.2</td>
<td>0.0</td>
</tr>
</tbody>
</table>

**/comments**

- Surveillance for Hepatitis B is passive in Germany; missing information
- Germany is considered as a low endemic country for hepatitis B.
- Laboratory evidence fulfills, the case meets the reference definition.
- Acute hepatitis B: Hospitalised cases/100000 NA NA NA 2.95 2.35
- Acute hepatitis B: Hospitalisation days per case NA NA NA 10.7 11.2
- Chronic hepatitis B: Hospitalised cases/100000 NA NA NA NA NA
- Chronic hepatitis B: Hospitalisation days per case NA NA NA NA NA
- Total: Hospitalised cases/100000 NA NA NA NA NA
- Total: Hospitalisation days per case NA NA NA NA NA
- Deaths (acute hepatitis B) 190 158 96 98 93
- Total number of patients with hepatocellular cancer NA NA NA NA NA
- Proportion of liver transplants due to hepatitis B NA NA NA NA NA
- Deaths (total number of deaths per 100 000) NA 0.19 0.12 0.12 0.11
- Total number of patients with hepatocellular cancer NA NA NA NA NA
- Proportion of liver transplants due to hepatitis B NA NA NA NA NA
- Deaths (total number of deaths per 100 000) NA 0.19 0.12 0.12 0.11

### Prevention

**by active immunisation**

1. Universal programme starting schedule coverage
2. Vaccination of infants 1995 2 months 0,1,6 73%5
3. Vaccination of adolescents 1995 10 years 0,1,6
4. Vaccination is also recommended for people with chronic liver diseases, HIV positives, mentally disabled, sex workers and prisoners that are arrested for a longer period of time.
5. In addition, travellers who are at risk for infection when travelling to countries with high
6. Reimbursement is decided on by Health Insurances but mostly all
7. Vaccination is also recommended for people with chronic liver diseases, HIV positives, mentally disabled, sex workers and prisoners that are arrested for a longer period of time. In addition, travellers who are at risk for infection when travelling to countries with high
8. Reimbursement is decided on by Health Insurances but mostly all

### Comments

- Surveillance for Hepatitis B is passive in Germany; missing information
- Germany is considered as a low endemic country for hepatitis B.
- Laboratory evidence fulfills, the case meets the reference definition.
- Surveillance for Hepatitis B is passive in Germany; missing information
- Germany is considered as a low endemic country for hepatitis B.
- Laboratory evidence fulfills, the case meets the reference definition.
- Surveillance for Hepatitis B is passive in Germany; missing information
- Germany is considered as a low endemic country for hepatitis B.
- Laboratory evidence fulfills, the case meets the reference definition.
- Surveillance for Hepatitis B is passive in Germany; missing information
- Germany is considered as a low endemic country for hepatitis B.
- Laboratory evidence fulfills, the case meets the reference definition.
- Surveillance for Hepatitis B is passive in Germany; missing information
- Germany is considered as a low endemic country for hepatitis B.
- Laboratory evidence fulfills, the case meets the reference definition.
- Surveillance for Hepatitis B is passive in Germany; missing information
- Germany is considered as a low endemic country for hepatitis B.
- Laboratory evidence fulfills, the case meets the reference definition.
- Surveillance for Hepatitis B is passive in Germany; missing information
- Germany is considered as a low endemic country for hepatitis B.
- Laboratory evidence fulfills, the case meets the reference definition.
- Surveillance for Hepatitis B is passive in Germany; missing information
- Germany is considered as a low endemic country for hepatitis B.
- Laboratory evidence fulfills, the case meets the reference definition.
- Surveillance for Hepatitis B is passive in Germany; missing information
- Germany is considered as a low endemic country for hepatitis B.
- Laboratory evidence fulfills, the case meets the reference definition.
- Surveillance for Hepatitis B is passive in Germany; missing information
- Germany is considered as a low endemic country for hepatitis B.
- Laboratory evidence fulfills, the case meets the reference definition.
- Surveillance for Hepatitis B is passive in Germany; missing information
- Germany is considered as a low endemic country for hepatitis B.
- Laboratory evidence fulfills, the case meets the reference definition.
- Surveillance for Hepatitis B is passive in Germany; missing information
- Germany is considered as a low endemic country for hepatitis B.
- Laboratory evidence fulfills, the case meets the reference definition.
- Surveillance for Hepatitis B is passive in Germany; missing information
- Germany is considered as a low endemic country for hepatitis B.
- Laboratory evidence fulfills, the case meets the reference definition.
- Surveillance for Hepatitis B is passive in Germany; missing information
- Germany is considered as a low endemic country for hepatitis B.
- Laboratory evidence fulfills, the case meets the reference definition.
- Surveillance for Hepatitis B is passive in Germany; missing information
- Germany is considered as a low endemic country for hepatitis B.
- Laboratory evidence fulfills, the case meets the reference definition.
- Surveillance for Hepatitis B is passive in Germany; missing information
- Germany is considered as a low endemic country for hepatitis B.
- Laboratory evidence fulfills, the case meets the reference definition.
- Surveillance for Hepatitis B is passive in Germany; missing information
- Germany is considered as a low endemic country for hepatitis B.
- Laboratory evidence fulfills, the case meets the reference definition.